Yitzhak Shamir Medical Center
Welcome,         Profile    Billing    Logout  
 6 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rachmiel, Marianna
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Recruiting
3
125
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
SURPASS-PEDS, NCT05260021 / 2021-003612-31: A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

Active, not recruiting
3
99
Europe, US, RoW
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Eli Lilly and Company, Eli Lilly and Company
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
07/24
02/25
ADVANCE, NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Not yet recruiting
3
125
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
NCT06075667: A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Recruiting
3
150
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
10/26
Heller, Lior
No trials found
Moravski, Gil
No trials found

Download Options